AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00053989
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: injection
Trial: NCT00239967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01820559
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT00166296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
Trial: NCT01440686
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, oral administrations
Trial: NCT04433234
Drug: DS-5141b
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once weekly
Trial: NCT00742092
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
Trial: NCT02141763
Drug: UCB4940 40 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Trial: NCT02141763
Drug: UCB4940 80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Trial: NCT02141763
Drug: UCB4940 160 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Trial: NCT02141763
Drug: UCB4940 240 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Trial: NCT02141763
Drug: UCB4940 320 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Trial: NCT02141763
Drug: UCB4940 560 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Active Substance: UCB4940~* Pharmaceutical Form: solution~* Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose~* Route of Administration: intravenous
Trial: NCT02693028
Drug: Probiotic lozenges
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Trial: NCT02693028
Drug: Placebo lozenges
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Trial: NCT02693028
Drug: Probiotic chewing gum
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
Trial: NCT02729051
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
Trial: NCT00530127
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dose and frequency as treatment
Trial: NCT00530127
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same dosage and frequency as study drug
Trial: NCT03687684
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-831 Matching Placebo Tablets.
Trial: NCT01584167
Drug: Cold crystalloid infusions, 0.9%NaCl or Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
Trial: NCT01273298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
Trial: NCT01577953
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.~Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
Trial: NCT02147158
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablet.
Trial: NCT00002837
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002837
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04371146
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo pill is administered once using a randomized placebo-controlled between subject's design
Trial: NCT02124265
Drug: CeraLyte 90
RxNorm normalized name: Electrolytes Oral Powder for Suspension [CERALYTE 90]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).~2. Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.~3. Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.~5. Patients will be monitored according to standard of care.~a. If gastric residuals are \>300cc, ORT will be stopped and only IV fluid resuscitation will be used.
Trial: NCT02981082
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
Trial: NCT02601989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per oral intake of placebo for six weeks
Trial: NCT01245946
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
Trial: NCT03148860
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: subjects will receive once weekly 15 mg (3 capsules) MTX
Trial: NCT00748982
Drug: AZD1305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Trial: NCT00748982
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
Trial: NCT01875939
Drug: Oral WCK2349
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
Trial: NCT01455935
Drug: Anti-platelets and statin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03129945
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
Trial: NCT01023945
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04673474
Drug: Hemay022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of Hemay022 tablet in fasted condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fed condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
Trial: NCT04673474
Drug: Hemay022
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single oral dose of Hemay022 tablet in fed condition on Day 1 of treatment period 1 followed by a single oral dose of Hemay022 tablet in fasted condition on Day 8 of treatment period 2. A washout period of 7 days will be maintained between the 2 treatment periods.
Trial: NCT04463420
Drug: PHR160 Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One puff spray per hour containing 300 mg of the drug will be given to patients. This treatment lasts up to 10 days.
Trial: NCT04463420
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: participants will receive a placebo spray every hour. This process will continue for 10 days.
Trial: NCT04463420
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: : Hydroxychloroquine 400 mg only on the first day / one naproxen 250 mg every 12 hours for 5 days / 500 mg azithromycin on the first day and 250 mg on the second to fifth days / 40 mg famotidine every 12 hours for 5 days / 25 mg prednisolone daily for 5 days
Trial: NCT03003494
Drug: Spiolto® Respimat®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: observations taken in a period of approximately 6 weeks
Trial: NCT01741519
Drug: LDLL600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
Trial: NCT03503370
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants randomized to the placebo will wash their feet using COMFORT BATH CLOTHS to wipe down their feet each day and then apply supplied chlorhexidine-compatible over-the-counter moisturizer.
Trial: NCT03773172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will mimic the active treatment.
Trial: NCT00400660
Drug: GSK615915A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
Trial: NCT00400660
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will also receive placebo inhaler.
Trial: NCT01364688
Drug: no drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no drug
Trial: NCT00511875
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo taken once daily for 24 months
Trial: NCT02460692
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Trial: NCT05251831
Drug: Intradermal injection
RxNorm normalized name: Dryvax Intradermal Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet-rich plasma (PRP) therapy uses injections of a concentration of a patient's own platelets.
Trial: NCT01316094
Drug: ASP1941
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01316094
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02460692
Drug: Vaporized Cannabis 3.7% THC/5.6% CBD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of vaporized cannabis plus either dronabinol or placebo pill
Trial: NCT02390102
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution 0.9%
Trial: NCT01237041
Drug: Placebo First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po four times on one of the inpatient days, then Niacin 500 mg po four times on another inpatient day
Trial: NCT00421720
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00421720
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02355938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 dose of placebo every 6 hours x 2 doses
Trial: NCT02635802
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time \>1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.~Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min.
Trial: NCT02160301
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT02160301
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT02160301
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PO
Trial: NCT04176419
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg orally at time of check-in to the preoperative unit
Trial: NCT04176419
Drug: Placebo Acetaminophen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg orally at time of check-in to the preoperative unit
Trial: NCT00569439
Drug: D5NS
RxNorm normalized name: Dextrose 5% in Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
Trial: NCT00569439
Drug: D10NS
RxNorm normalized name: Dextrose 10% in Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
Trial: NCT04597931
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: IV Zoledronic acid 5 mg
Trial: NCT02481856
Drug: SQ tree SLIT-tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02481856
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04176419
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg orally at time of check in to the preoperative unit
Trial: NCT00000431
Drug: PDGF-B/Ad5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
Trial: NCT03764072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsules for oral administration.
Trial: NCT02944552
Drug: polyene phosphatidylcholine capsule 456mg
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the positive drug control group administrated polyene phosphatidylcholine capsules 456mg and two bicyclol blank analog tablets orally, three times daily for 4-8 weeks.
Trial: NCT00809471
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minutes orally prior to initiation of sexual activity
Trial: NCT02355028
Drug: LHA510 vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used as a placebo comparator
Trial: NCT00471341
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00471341
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04731090
Drug: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
Trial: NCT00410735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg BID for 12 weeks
Trial: NCT04285255
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: opioids anaesthesia
Trial: NCT01057810
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
Trial: NCT05973305
Drug: Trusopt 20 mg/ml
RxNorm normalized name: Trusopt 20 MG/ML Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosing schedule t.i.d.
Trial: NCT01592331
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT01592331
Drug: RO5508887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose
Trial: NCT03187548
Drug: Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste
RxNorm normalized name: caseins
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
Trial: NCT01905202
Drug: Secretrol
RxNorm normalized name: gonorrheal urethral secretion human
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04512196
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline contains 0.9% sodium chloride.
Trial: NCT01931475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02794792
Drug: Ipragliflozin L-proline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02794792
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT00596817
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules, daily, orally
Trial: NCT02156908
Drug: D-serine
RxNorm normalized name: D-Serine
DrugBank: D-Serine (DB03929)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-serine 60 mg/kg
Trial: NCT00443079
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill 3 times daily x 6 weeks
Trial: NCT01417091
Drug: BPS804
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01351792
Drug: Foster® 100/6 µg/unit dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).
Trial: NCT01351792
Drug: Symbicort® Turbohaler® 200/6 μg/actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
Trial: NCT01901601
Drug: Topical Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00691912
Drug: liposomal Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
Trial: NCT03106363
Drug: Placebo alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
Trial: NCT04080024
Drug: SN132D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel manganese-based macromolecular MRI contrast agent
Trial: NCT01578473
Drug: Testosterone Pellets
RxNorm normalized name: testosterone pellets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
Trial: NCT01873430
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03618173
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline serum at the dose of 0,2mL/kg maximum 8mL